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Abstract: Formaldehyde (HCHO) and protoporphyrin, are in connection with redox homeostasis. Data show the impor-
tance of HCHO in proliferative as well as in apoptotic processes. Free protoporphyrin can be detected near the Zn-
protoporphyrin in cancer and it has pro- and antioxidant forms depending on concentrations. The aim was to determine the 
amount of HCHO and protoporphyrin concentrations of erythrocytes in colorectal cancer after colectomy and to estimate 
redox homeostasis. Total 32 adult patients after 5-10 years of colectomy and 9 healthy volunteers were drawn into this 
study. Tumor markers, redox parameters, HbA1c, HCHO and protoporphyrin concentrations were measured. Erytrocyte 
HCHO was significantly lower in colectomysed patients, than in controls. Protoporphyrin concentration was low in pa-
tients, but in metastasis its concentration was significant. HbA1c correlated significantly with free radicals and decreased 
the antioxidant status of erythrocytes. HCHO and protoporphyrin concentrations of erythrocytes and the total scavenger 
capacity are very important indexes in cancer. 
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INTRODUCTION 
  Colorectal cancers are one of the most frequent types of 
cancers in Hungary as well as in the USA. Often the diseases 
are observed only in Dukes B and C stages or later stages 
and tumor markers can show false negative results. 
  The resection of cancerous tissues does not prevent the 
eventual recurrence of the cancer therefore it is very impor-
tant to check for recidives or metastasis. The survival sig-
nificantly depends on the early recognition of metastases. 
  HCHO is genotoxic and carcinogen. It can be found in 
animal tissues in a special bounded form, mainly in hy-
droxymethyl form. Endogenous HCHO is produced partly by 
enzymatic demethylation of different N-, S-, and O- methy-
lated compounds [1, 2]. S-adenosyl-methionine is an impor-
tant methyl donor in several biological transmethylation re-
actions. The product of the S-adenosyl-homocysteine inhib-
its the transmethylation process because this molecule is 
hydrolysed to adenosine and L-homocysteine by the action 
of S-adenosyl-homocysteine hydrolase [3]. The accumula-
tion of homocysteine leads to increased cellular oxidative 
stress [4]. DNA methylation typically occurs at the cytosine 
– phosphate – guanine site. This methylation results in the 
conversion of the cytosine to 5-methyl-cytosine. As the re-
sult of this methylation in the conversion of the cytosine is 
converted into 5-methyl-cytosine. This reaction is catalysed by 
DNA methyltransferase. The methylation stage of this region  
 
 
*Address correspondence to this author at the II. Department of Medicine, 
Semmelweis University, H-1088, Szentkirályi St. 46. Budapest, Hungary; 
E-mail: blaz@bel2.sote.hu 
can  have a major    impact  on  gene   functions  [5].  Since the 
endogenous transmethylation processes occur via  HCHO, 
this molecule can be considered as an ancient and basic 
compound of life systems [1, 6, 7]. Some quaternary ammo-
nium compounds, such as N
–trimethyl-L-lysine or choline 
are potential HCHO generators as well [2]. It was also veri-
fied, that arginine (38), methionine (65) and lysine (72) near 
the methionine (80) are methylated and coordinated towards 
the central iron of heme [8]. 
  The protoporphyrin IX. heterocyclic macromolecule is 
formed by the activity of protoporphyrinogen oxidase, and 
this molecule will be the substrate of ferrochelatase to form 
heme in the process of hemoglobin biosynthesis. It is well 
known that hemoglobin biosynthesis occurs partly in cytosol 
and the mitochondrion, and than heme and globine are con-
nected with each other in the cytosol. 
  Porphyrins combine readily with metals. Hemoglobin 
contains iron or zinc. Porphyrines are also very ancient 
molecules in the flora and fauna [9, 10]. 
  Iron-porphyrine proteins represent an important group of 
redoxy enzymes, such as catalase, peroxidase, cytochrome c 
and so on. Cytochrome c methylation processes were de-
scribed in arginine, methionine and lysine by specific meth-
yltransferases [11]. Biological transmethylation - in which 
HCHO cannot be released - is very important for its struc-
tural and functional aspects [12-16]. For example both L-
arginine supplementation and deprivation influence cell pro-
liferation. The diverse biological effects of L-arginine and its 
methylated derivatives encourage further experiments [17]. It 
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e.g. glutathione. 
1O2 is produced in the reaction of HCHO 
and H2O2 [18]. 
  The captured formaldehyde is originated from dynamic 
methylation and demethylation processes in which this sim-
plest aliphatic aldehyde is bound in form of highly reactive 
hydroxymethyl groups. The basis of the formaldemethone 
formation is that the small quantity of HCHO in equilibrium 
with the hydroxymethyl groups will react with dimedone to 
form formaldemethone. This will disturb the equilibrium and 
more HCHO will be formed, which, in turn, will react with 
the dimedone [2]. 
  In case of colorectal tumors both primer and secunder 
preventions have very important roles. In previous papers, 
we gave account that the erythrocyte redox state is a very 
good indicator of the severity of different gastrointestinal 
diseases [19-22]. We wanted to know, whether the recent 
developed simple routine methods were suitable to examine 
the recidive or metastasis of colectomysed patients. The 
question is whether the operation and its follow up chemo-
therapy and radiotherapy will still be effective in later years? 
The further aims of this study are to determine the HCHO 
and protoporphyrin concentrations of erythrocytes in colo-
rectal cancer after colectomy and to examine the connection 
of molecules such as free radicals, HCHO and protoporphy-
rin, to establish the concentration ratios of the active mole-
cules in erythrocyte of colectomised patients, and to explain 
their roles in the redox homeostasis. 
MATERIALS AND METHODS 
  Materials. 1,1-diphenyl-2-picrylhydrasyl stable radical, 
luminol, hydrogen peroxide and microperoxidase were ob-
tained from SIGMA (St. Louis). Tumor marker CEA, CA 
19-9, AFP and PSA kits (LIA-mAT immunoluminometry) 
were obtained from LIA-mAT (Budapest) and HbA1c-kit 
from BioRad (Budapest). CRP (CRP/AUT-000) was ob-
tained from Diagnosticum Ltd. GSHPx and SOD kits were 
purchased from RANDOX (England). All other reagents in 
analytical grade were purchased from Reanal (Budapest). 
  Patients. Caucasian volunteers, 32 adult patients (18 
male and 14 female) (aged: 60,4 ± 8,8 years) after 5-10 years 
of their colectomy and chemotherapy (N=32) and radiother-
apy (N=8) and 9 healthy volunteers (4 male and 5 female) 
(aged: 55,8±9,7 years) were drawn into this study. Nine con-
trol patients and 20 Dukes B and 5 Dukes C patients were 
included in the study, all of them being free of complaints. 
They underwent routine examinations as well as 3D abdomi-
nal ultrasound examinations. Patients with positive routine or 
3D ultrasound examinations underwent further examinations 
(endoscopy and CT). 
  Tumor markers (CEA, CA 19-9, AFP / Berthold Lumat 
9501 manual instrument), CRP, redox parameters, HbA1c 
(Variant II. HPLC method), HCHO and protoporphyrin con-
centrations in the erythrocyte were measured with routine 
laboratory parameters together. Patients with Dukes B and C 
after operation received same recommended standard ther-
apy. 
  Permission number: TUKEB 167/1997, 15/2004 and 
IKEB 3944/2004. 
 
SEPARATION OF PLASMA AND ERYTHROCYTES 
  Plasma and erythrocyte were separated using the standard 
methods. The hemoglobin content was adjusted to 10 g% 
uniformly for the measurements. 
 OPLC  analysis.  Totality of molecular participants in 
transmethylating processes are not known, although the 
quantity of bounded HCHO could be detected in dimedon 
adduct form (after 24 hours) analytically. 
  The formaldehyde in dimedone adduct form (formalde-
methone) was identified and determined by chromarographic 
methods using an authentic substance [23]. The samples 
were treated with dimedone solution (0.07% dimedone in 
methanol) (e.g. 0.7 cm
3 sample / 0.7 cm
3 of dimedone solu-
tion). This suspension was centrifuged at 1500 g for 10 min-
utes at 4
0C. The clear supernatants were used to chroma-
tographic separations [1, 23]. 
  The chromatographyc separations were carried out on 
TLC silica gel 60F254 precoated chromatoplates (Merck Co., 
Germany) using chloroform - methylenechloride mixture 
(35/65, v/v) for formaldemethone determination. Samples 
were applied with a NANOMAT sample applicator 
(CAMAG, Switzerland). Calibration curves were prepared 
using an authentic substance. For densitometric determina-
tion a Shimadzu CS-930  TLC/HPTLC scanner (Shimadzu 
Co., Japan), =265 nm was used. 
  Redox-state measurements. The reducing-power of the 
sample was determined at 700 nm according to Oyaizu [24] 
based on the chemical reaction Fe[III]Fe[II]. Increased 
absorbance indicated increased reducing-power, which was 
also expressed as an ascorbic acid equivalent (mmol/L 
eqAS). 
  The hydrogen-donating ability of the sample was esti-
mated in the presence of 1,1-diphenyl-2-picrylhydrazyl radi-
cal according to Hatano et al. [25]. 
  Free SH-group concentration was measured by the 
method of Sedlak based on the Ellmann reaction [1985]. All 
spectrophotometic methods were carried out with Jasco V 
550 spectrophotometer [Jasco Co., Japan] [26]. 
  A simple method of luminol-dependent chemilumines-
cence [H2O2/OH
.-microperoxidase-luminol system] was ap-
plied to study the antioxidant protective mechanisms in 
colectomysed patients. Total scavenger capacity (TSC) of 
the plasma and erythrocytes was measured by this assay 
adapted to a Berthold Lumat 9501 manual instrument (Ber-
thold GmbH, Germany) [19]. 
 Protoporphyrin  detection.  Erythrocyte protoporphyrin 
IX was measured by the flourimetric method using JascoFP 
6300 type fluorometer (Jasco Co, Japan). Simple micro-
method was adapted for purification of protoporphyrin by 
Chisolm and coworkers [1975]. The excitation wavelength 
was at = 405 nm and the emission at = 610 nm [27]. 
  One-way ANOVA statistical analysis was applied to 
evaluate the significance between patient groups. 
  The present table means ± S.D. Each measuring point 
represents five parallel data in luminol-dependent chemilu-
minescence experiments when c.v.% was under 5.00%. Sig-
nificance level was determined at P<0.05. 8    The Open Medicinal Chemistry Journal, 2008, Volume 2  Blázovics et al. 
RESULTS 
 Table  1 shows the tumor marker parameters (CEA, CA 
19-9, AFP) and CRP concentration of colectomised patients 
and healthy controls. CA 19-9 concentration of colectomised 
patients was significantly higher than that of controls, but the 
data were in normal range. There were no significant differ-
ences between genders in the measured parameters and 
therefore we did not separate the data of men from the 
women in the tables. 
  Four simple redox measurements, H-donating ability, 
reducing-power, free SH-group concentration and stimulated 
chemiluminescent intensity of plasma and erythrocytes were 
performed to evaluate the redox homeostasis in colectomy-
sed patients compared to the control values. It can be estab-
lished from these data after 5-10 years of colectomy, that the 
sick patients’ antioxidant defense system differed from the 
healthy patients’. Free SH-group concentration and reduc-
ing-power were found to change in a parallel way in the 
plasma and antiparallel with the chemiluminescence inten-
sity of plasma. The erythrocyte total scavenger capacity of 
operated patients was significantly lower than that of the 
control group. On the basis of our present work high eryth-
rocyte chemiluminescence intensity indicates low antioxi-
dant capacity in colectomysed patients compared to healthy 
controls (Table 2). HbA1c level correlated significantly the 
decreased antioxidant status of the erythrocyte. GSHPx and 
SOD activity were measured as well. Only the SOD activity 
was significantly decreased of the enzymatic antioxidant 
defense system. 
  Measurable amount of HCHO concentration of erythro-
cytes was also significantly lower in colectomised patients, 
than in healthy volunteers (Table 3). Protoporphyrin concen-
tration was very low in patients without metastasis and signifi-
cantly higher value in colectomised patients after the Dukes C 
stage. 
  Seven patients were omitted from the tables, because 
they had protoporphyrin IX in very high concentration (600-
800 nmol/L erythrocyte). The significantly lower amount of 
HCHO of erythrocyte was detected in five patients. It was 
lower than that of other operated patients and healthy con-
trols. In these cases severe metastatic processes could be 
observed in cancerous patients and free protoporphyrin could 
be detected (Figs. 1,2). 
  The data of seven patients were raised from the colec-
tomised groups, because one woman was operated with 
mamma tumor before colectomy (HCHO cc: =2.83 x 10
-3 
μmol/mg erythrocyte), one man was treated with Xeloda 
because of liver metastasis (HCHO cc: 1.23 x 10
-3 μmol/mg 
erythrocyte), five men had prostate problems, but only in 
three cases from them was tumor diagnosis established. The 
mean erythrocyte HCHO concentration of patients with pros-
tate tumor was 1.53 x 10
-3 ± 2.03 x 10
-4 μmol/mg erythrocyte 
(PSA: 11.58 ± 9,02 ng/mL). 
DISCUSSION 
  It is well known, that in neoplasia “methylation imbal-
ance” can be observed. Hypomethylation is accompanied by 
localized hypermethylation and an increase in expression of 
DNA methyltransferase [5, 12]. Genome-wide hypomethyla-
tion can lead to chromosome instability, and hypomethyla-
tion leads to elevated mutation rates [13]. Protoporphyrin IX 
generally is accumulated in more cancerous cells, than in 
healthy ones and autofluorescence lifetime is extended in 
cancer tissues. This fluorophore property of protoporphyrin 
is often applied in photodynamic therapy [28]. Because of all 
these, the idea arises, that the pool of bounded HCHO is not 
enough for all methylating processes in the tissues, and 
therefore protoporphyrin also occurs in the erythrocyte. 
Since methylation activity is low, hemoglobin does not form. 
Our results showed that in tumorous patients the protopor-
firin IX – according to concentration – induces free radicals 
Table 1.  Parameters of Colectomised Patients 
 
Groups  CEA [ng/mL] [nr: 0 - 5]  CA 19-9 [U/mL] [nr: 3.5 - 37]  AFP [U/mL] [nr: 0.5 - 11]  CRP [mg/L] [nr: < 5] 
Control [N= 9 ]  2.8 ± 1.4  3.8 ± 2.3  4.5 ±1.9 2.34  ± 1.59 
Colectomised Patients  
[N=20] [Dukes B]  1.7 ± 1.2  10.5 ± 6.7  4.1 ± 1.5  3.28 ± 2.59 
Colectomised Patients  
[N= 5] [Dukes C]  1.4 ± 0.8  15.8 ± 7.1  4.7 ± 3.0  4.84 ± 6.16 
Significance: [P<0.05] 
1 vs 2 
1 vs 3 
1 vs 2 
1 vs 3  n.s. n.s. 
Table 2.  Parameters of Colectomised Patients 
 
Groups  Erythrocyte CL-
Intensity [RLU%] 
Plasma CL-
Intensity [RLU%] 
Plasma H-Donor 
Activity [%] 
Plasma Free SH-
Group [mmol/L] 
Plasma Reducing-Power 
[mmol/LeqAS] 
Control [N= 9 ]  89.1 ± 11.4  7.9 ± 4.3  60.1 ± 7.5  0.68 ± 0.08  1.33 ± 0.29 
Colectomised Patients [N=20]  
[Dukes B]  103.1 ± 14.3  10.3 ± 7.9  59.9 ± 4.4  0.55 ± 0.12  1.12 ± 0.22 
Colectomised Patients [N=5]  
[Dukes C]  99.74 ± 12.33  9.6 ± 8.0  62.5 ± 4.7  0.58 ± 0.06  1.13 ± 0.17 
Significance: [P<0.05]  1 vs 2  n.s.  n.s. 
1 vs 2 
1 vs 3  n.s. Redox Homeostasis in Colorectal Cancer  The Open Medicinal Chemistry Journal, 2008, Volume 2    9 
in small concentration and scavenges in higher concentra-
tion. At the same time beside the high protoporphyrin con-
centration the HCHO concentration was significantly low in 
metastatic tumorous patients. We think that erythrocyte 
measurements (redox homeostasis, HCHO and protoporphy-
rin) will bring us closer to get to know tumorous inclinations 
better. Determination of free protoporphyrin and bounded 
HCHO (mobilized methyl group) is suitable to differentiate 
the grade of diseases, when the results of tumor marker ex-
aminations are doubtful. 
 
Fig. (1). Standard curve of protoporphyrin. 
 
Fig. (2). Free protoporphyrin concentration of erythrocyte in metas-
tasis of colorectal cancer. 
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ABBREVIATIONS 
AFP =  Alpha  fetoprotein 
CA 19-9  =  Carbohydrate antigen 
CEA =  Carcinoembrionic  antigen 
CRP  =  C reactive protein 
HbA1c =  Oxidized  hemoglobin 
HCHO =  Formaldehyde 
OPLC  =  Over pressured layer chromatography 
PSA  =  Prostate specific antigen 
TSC  =  Total scavenger capacity 
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